MARSEILLE, France, March 16 /PRNewswire/ --
- WT1 is a Valuable Biomarker in the Prognosis and Follow-up of Acute Myeloid Leukemia (AML) Patients.
- The ProfileQuant(R) WT1 kit was Developed and Validated in the Context of an International Collaborative Study Coordinated by the European Leukemia Network (ELN) Consortium.
- With its WT1 kit, Ipsogen Continues its CE Marking Strategy and Confirms its Leadership Position in Molecular Diagnosis of Leukemia.
IPSOGEN SA (Alternext - FR0010626028 - ALIPS), a molecular diagnostic company specialized in the development, manufacturing and commercialization of diagnostic assays for breast cancer and leukemias, today announces the CE marking of its ProfileQuant(R) WT1 kit.